China Pioneer Pharma Holdings Limited (02096) has signed an exclusive licensing agreement with Ipsen for SIM0613 (LRRC15 antibody conjugate drug).

Zhixin Financial News APP, Sinopharm Group (02096) announced that on December 19, 2025, its subsidiary Jiangsu Sinopharm Zaiming Pharmaceutical Co., Ltd. (Jiangsu Zaiming) signed an exclusive licensing agreement with Ipsen Pharma SAS (listings on Euronext: IPN; ADR trading code: IPSEY) (Ipsen). According to the terms of the agreement, Ipsen will obtain global exclusive rights outside the Greater China region to develop, manufacture, and commercialize the antibody-drug conjugate (ADC) SIM0613 targeting LRRC15 developed by Jiangsu Zaiming.